Drug management of hypertensive disorders of pregnancy

Pharmacology and Therapeutics

Volumn 74, Issue 2, 1997, Pages 221-258

  Khedun, S M ^a   Moodley, J ^a   Naicker, T ^a   Maharaj, B ^b  

^a UNIVERSITY OF NATAL   (South Africa)

^b NONE

Author keywords

Antihypertensive agents; Eclampsia; Hypertension in pregnancy; Preventative agents

Indexed keywords

ACEBUTOLOL; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; ANTICONVULSIVE AGENT; ANTIHYPERTENSIVE AGENT; ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM ANTAGONIST; CLONIDINE; DIAZOXIDE; DIHYDROPYRIDINE DERIVATIVE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDRALAZINE; HYDROCHLOROTHIAZIDE; ISRADIPINE; KETANSERIN; LABETALOL; METHYLDOPA; METOPROLOL; NICARDIPINE; NIFEDIPINE; NIMODIPINE; NITRENDIPINE; NITROPRUSSIDE SODIUM; PINDOLOL; PRAZOSIN; SEROTONIN ANTAGONIST; THIAZIDE DIURETIC AGENT; UNINDEXED DRUG; URAPIDIL; VASODILATOR AGENT;

ANTIHYPERTENSIVE THERAPY; BRADYCARDIA; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CONVULSION; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG INDUCED DISEASE; DRUG MECHANISM; DRUG METABOLISM; DRUG SAFETY; ECLAMPSIA; GASTROINTESTINAL TOXICITY; HUMAN; HYPERGLYCEMIA; HYPERTENSION; HYPOTENSION; INTRAVENOUS DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; MATERNAL HYPERTENSION; NEUROTOXICITY; ORAL DRUG ADMINISTRATION; PREECLAMPSIA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REVIEW; TREATMENT INDICATION;

EID: 0030792251     PISSN: 01637258     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0163-7258(97)82005-0     Document Type: Article

References (321)

1. Ablad B. A study on the mechanism of the hemodynamics effects of hydralazine in man. Acta Pharmacol. Toxicol. 20:1963;1-53. (Suppl. 1).
2. Allen J., Maigaard S., Forman A., Jacobsen P., Jespersen L.T., Hansen K.P.B. Acute effects of nitrendipine in pregnancy induced hypertension. Br. J. Obstet. Gynaecol. 94:1987;222-226.
3. Altura B.M., Altura B.T., Carella A. Magnesium deficiency induced spasms of umbilical vessels: relation to pre-eclampsia, hypertension, growth retardation. Science. 221:1983;376-378.
4. Andersson K.E., Ingemarsson I., Ulmesten U., Wingerup L. Inhibition of prostaglandin-induced uterine activity by nifedipine. Br. J. Obstet. Gynaecol. 86:1979;175-179.
5. Arndts D. New aspects of the clinical pharmacology of clonidine. Chest. 83:1983;397-400. (Suppl.).
6. Arnold K., Gerber N. The rate of decline of diphenylhydantoin in human plasma. Clin Pharmacol. Ther. 11:1970;121-134.
7. August P., Lindheimer M.D. Pathophysiology of pre-eclampsia. Laragh J.H., Brenner B.M. 2nd edn. Hypertension: Pathophysiology, Diagnosis, and Management. 1995;2407-2426 Raven Press, New York.
8. Fish-oil and pre-eclampsia. Br. J. Obstet. Gynaecol. 98:1991;737-740.
9. Management of hypertension in pregnancy: executive summary Australian Society for the Study of Hypertension in Pregnancy. Management of hypertension in pregnancy: consensus statement. Med. J. Aust. 158:1993;700-702.
10. Baker L., Stanley C.A. Neonatal hypoglycaemia. Curr. Ther. Endocrinol. Metab. 5:1994;376-380.
11. Barry C., Fox R., Stirrat G. Upper abdominal pain in pregnancy may indicate pre-eclampsia. Br. Med. J. 308:1994;1562-1563.
12. Barth N., Alvan G., Borga O., Sjoqvist F. Two fold interindividual variation in plasma protein binding of phenytoin in patients with epilepsy. Clin. Pharmacokinet. 1:1976;444-452.
13. Barton J.R., Sibai B.M., Ahoka R.A., Whybrew W.D., Mercer B.M. Magnesium therapy in preeclampsia is associated with increased urinary cyclic guanosine monophosphate excretion. Am. J. Obstet. Gynecol. 167:1992;931-934.
14. Bateman D.N., Hobbs D.C., Twomey T.M., Stevens E.A., Rawlins M.D. Prazosin pharmacokinetics and concentration effect. Eur. J. Clin. Pharmacol. 16:1979;177-181.
15. Beaufils M. Is low-dose aspirin effective in preventing hypertension in pregnancy? Curr. Opin. Nephrol. Hypertens. 3:1994;237-240.
16. Beaufils M., Uzan S., Donsimoni R. Prevention of pre-eclampsia by early antiplatelet therapy. Lancet. i:1985;840-842.
17. Beermann B. Aspects of pharmacokinetics of some diuretics. Acta Pharmacol. Toxocol. 54:1984;17-32. (Suppl. 1).
18. Belfort M.A., Moise K.J. Effect of magnesium sulphate on maternal brain blood flow in pre-eclampsia: a randomised placebo controlled study. Am. J. Obstet. Gynecol. 167:1992;661-666.
19. Belfort M.A., Saade G.R., Moise K.J. Effect of magnesium on maternal retinal blood flow in preeclampsia: a randomised placebo controlled study. Am. J. Obstet. Gynecol. 167:1992;1548-1553.
20. Belfort M.A., Saade G.R., Moise K.J., Cruz A., Adam K., Kramer W., Kirshon B. Nimodipine in the management of pre-eclampsia: maternal and fetal effects. Am. J. Obstet. Gynecol. 171:1994;417-424.
21. Belizan J.M., Villar J. The relationship between calcium intake and oedema, proteinuria and hypertension-gestosis: a hypothesis. Am. J. Clin. Nutr. 33:1980;2200-2210.
22. Belizan J.M., Villar J., Gonzailez L. Calcium supplementation to prevent hypertensive disorders of pregnancy. N. Engl. J. Med. 325:1991;1399-1405.
23. Bergstrom S., Povey G., Songane F., Ching C. Seasonal incidence of eclampsia and its relationship to meterological data in Mozambique. J. Perinat. Med. 20:1992;150-158.
24. Bhorat I.E., Naidoo D.P., Rout C.C., Moodley J. Malignant ventricular arrhythmias in eclampsia. A comparison of labetalol with dihydralazine. Am. J. Obstet. Gynecol. 168:1993;1292-1296.
25. Bigger J.T., Schmidt D.H., Kutt H. Relationship between the plasma level of diphenylhydantoin sodium and its cardiac antiarrythmic effect. Circulation. 38:1968;363-374.
26. Blakeley A.G.H., Summers R.J. The effects of labetalol (AH 5158) on adrenergic transmission in the cat spleen. Br. J. Pharmacol. 59:1977;643-650.
27. Bochner F., Hooper W.D., Tyrer J.H., Eadie M.J. The effect of dosage increments on blood phenytoin concentrations. J. Neurol. Neurosurg. Psychiatry. 35:1972;873-876.
28. Thiazide diuretics. Bochner F., Carruthers G., Kampman J., Steiner J. 2nd edn. Handbook of Clinical Pharmacology. 1983;319-321 Little Brown, Boston.
29. Bongrani S., Razzetti R., Schiantarelli P. Cardiovascular effects of nicardipine in anaesthetized open-chest dogs in the absence and presence of beta-adrenergic receptor blockade: a comparison with nifedipine and verapamil. J. Cardiovasc. Pharmacol. 7:1985;889-905.
30. Boulos B.M., Davis L.E., Almond C.H., Jenkins W.L., Hama F. Placental transfer of diazoxide and its hazardous effect on the newborn. J. Clin. Pharmacol. 11:1971;206-210.
31. Bourget P., Fernandez H., Ribou F., Edouard D., Frydman R. Weak transplacental passage of prazosin during the third trimester of pregnancy. 3 cases. J. Gynecol. Obstet. Biol. Reprod. 22:1993;871-874. (Paris).
32. Brennecke S.P., Brown M.A., Crowther C.A., Hague W.M., King J., McCown L., Morris J., North R., Pattison N., Tippett C. Aspirin and prevention of pre-eclampsia. Position statement of the use of low dose aspirin in pregnancy by the Australasian Society for the Study of Hypertension in Pregnancy. Aust. N. Z. J. Obstet. Gynaecol. 35:1995;38-41.
33. Brent R.L., Beckman D.A. Angiotensin-converting enzyme inhibitors, embryopathic class of drugs with unique properties: information of clinical teratology counsellors. Teratology. 43:1991;543-546.
34. Brittain R.T., Levy G.P. A review of animal pharmacology of labetalol, a combined α- and β-adrenoceptor blocking drug. Br. J. Clin. Pharmacol. 3:1976;681-684. (Suppl. 3).
35. Brogden R.N., Heel R.C., Speight T.M., Avery G.S. Prazosin: a review of its pharmacological properties and therapeutic efficacy in hypertension. Drugs. 14:1977;163-197.
36. Brown H.G. Clinical pharmacological observations on atenolol a beta adrenoceptor blocker. Clin. Pharmacol. Ther. 20:1976;524-534.
37. Bucher H.C., Guyatt G.H., Cook R.J., Hatala R., Cook D.J., Lang J.D., Hunt D. Effect of calcium supplementation on pregnancy-induced hypertension and preeclampsia: a meta-analysis of randomized controlled trials. JAMA. 275:1996;1113-1117.
38. Bulmer J.N. Immune aspects of pathology of the placental bed contributing to pregnancy pathology. Ballieres Clin. Obstet. Gynaecol. 6:1992;461-488.
39. Bulstra-Ramkers M.T.E., Huisjes H.J., Visser G.H.A. The effects of 3G eicosapentaenoic acid on recurrence of intrauterine growth retardation and pregnancy induced hypertension. Br. J. Obstet. Gynaecol. 102:1995;123-126.
40. Cambridge D., Davey M.J., Massingham R. Prazosin, a selective antagonist of post-synaptic alpha-adrenoceptors. Br. J. Pharmacol. 59:1977;P514-P515.
41. Canez M.S., Reed R.L., Sheuken I. Effect of maternal magnesium sulphate treatment on fetal heart rate variability. Am. J. Perinatol. 4:1987;167-170.
42. Carbonne B., Jannet D., Touboul C., Khelifati Y., Milliez J. Nicardipine treatment of hypertension during pregnancy. Obstet. Gynecol. 81:1993;908-914.
43. Carlan S.J., O'Brian W.E. The effect of magnesium sulphate on the biophysical profile of normal term fetuses. Obstet. Gynecol. 77:1991;681-684.
44. Carrolli G., Duley L., Belizan J.M., Villar J. Calcium supplementation during pregnancy: a systemic review of randomised controlled trials. Br. J. Obstet. Gynaecol. 101:1994;753-758.
45. Chamberlain G. Raised blood pressure in pregnancy. Br. Med. J. 302:1991;1454-1458.
46. Chari R.S., Friedman S.A., Sibai B.M. Antihypertensive therapy during pregnancy. Fet. Mat. Med. Rev. 7:1995;61-75.
47. Chellingworth M.C., Willis J.V., Broadfoot C.M., Kendall M.J. Pharmacokinetics and pharmacodynamics of isradipine (PN-200-110) in young and elderly patients. Am. J. Med. 84:1988;72-79. (Suppl. B).
48. Chissell S., Botha J.H., Moodley J., McFadyen L. Intravenous and intramuscular magnesium sulphate regimens in severe pre-eclampsia. S. Afr. Med. J. 84:1994;607-610.
49. CLASP: a randomised trial of low dose aspirin for the prevention and treatment of pre-eclampsia among 9364 pregnant women. Lancet. 343:1994;619-629.
50. Low dose aspirin in pregnancy and early childhood developments: follow-up of Collaborative Low-dose Aspirin Study in Pregnancy. Br. J. Obstet. Gynaecol. 102:1996;861-868.
51. Cockburn J., Moar V.A., Ounstd N.M., Redman C.W.G. Final report on study on hypertension during pregnancy: the effects of specific treatment on the growth and development of the children. Lancet. i:1986;647-649.
52. Cohn N., Burke P. Nitroprusside. Ann. Intern. Med. 91:1979;752-757.
53. Collins R., Yusuf S., Peto R. Overview of randomised trials of diuretics in pregnancy. Br. Med. J. 290:1985;17-23.
54. Conradt A., Weidinger H., Algayer H. On the role of magnesium in foetal hypotrophy, pregnancy induced hypertension and preeclampsia. Mag. Bull. 6:1984;68-76.
55. Cotton D.B., Gonik B., Dorman K.E. Cardiovascular alterations in severe pregnancy-induced hypertension: acute effects of intravenous magnesium sulphate. Am. J. Obstet. Gynecol. 148:1984;162-165.
56. Cotton D.B., Janusz C.A., Berman R.F. Anticonvulsant effect of magnesium sulphate on hippocampal seizures: therapeutic implications in pre-eclampsia-eclampsia. Am. J. Obstet. Gynecol. 166:1992;1127-1136.
57. Coyaji K.J., Otiv S.R. Single dose of intravenous sodium for the treatment of eclampsia. Acta Obstet. Gynecol. Scand. 69:1990;115-118.
58. Crowther C.A. Eclampsia at Harare Maternity Hospital. An epidemiological study. S. Afr. Med. J. 68:1985;927-929.
59. Crowther C. Magnesium sulphate versus diazepam in the management of eclampsia: a randomised controlled trial. Br. J. Obstet. Gynaecol. 97:1990;110-117.
60. Cruikshank D.J., Robertson A.A., Campbell D.M., MacGillivary I. Does labetalol influence the development of proteinuria in pregnancy hypertension? A randomised controlled study. Eur. J. Obstet. Gynecol. 45:1992;47-51.
61. Cunningham F.G., Pritchard J.A. How should hypertension during pregnancy be managed? Experience at the Parkland Memorial Hospital. Med Clin. North Am. 68:1984;505-526.
62. Hypertensive disorders in pregnancy. Cunningham F.G., MacDonald P.C., Gant N.F. Williams Obstetrics. 1989;653-694 Appleton and Lange, Norwalk.
63. Davey D.A., Anthony J. Hypertension and antihypertensive drugs in pregnancy. Cardiovasc. J. S. Afr. 3:1990;154-161.
64. Davies D.S., Wing L.M.S., Reid J.L., Neill E., Tippett P., Dollery C.T. Pharmacokinetics and concentration effect relationship of intravenous and oral clonidine. Clin. Pharmacol. Ther. 21:1977;593-601.
65. Dayton P.G., Perel J.M. Physiological and physiochemical bases of drug interactions in man. Ann. NY Acad. Sci. 179:1971;67-87.
66. DeClerck F. Review: blood platelets in human essential hypertension. Agents Actions. 18:1986;563-580.
67. Dekker G.A., Sibai B.M. Low dose aspirin in the prevention of preeclampsia and fetal growth retardation: rationale, mechanisms, and clinical trials. Am. J. Obstet. Gynecol. 168:1993;214-227.
68. Delorenzo R.J. Phenytoin: calcium- and caldmodium-dependent-protein phosphorylation and neurotransmitter release. Glaser G.H., Penry G.K., Woodbury D.M. Antiepileptic Drug: Mechanism of Action. 1980;399-414 Raven Press, New York.
69. DiSessa T.G., Moretti M.L., Khoury A., Pullium D.A., Arheart K.L., Sibai B.M. Cardiac function in fetuses and new born exposed to low-dose aspirin during pregnancy. Am. J. Obstet. Gynecol. 171:1994;892-900.
70. Dollery C.T., Harrington M. Methyldopa in hypertension: clinical and pharmacological studies. Lancet. i:1962;759-763.
71. Dommisse J. Phenytoin sodium and magnesium sulphate in the management of eclampsia. Br. J. Obstet. Gynaecol. 97:1990;104-109.
72. Dommisse J., Davey D.A., Roos P.J. Prazosin and oxprenolol therapy in pregnancy hypertension. S. Afr. Med. J. 64:1983;231-233.
73. Donaldson J.O. The case against magnesium sulphate for eclamptic convulsions. Int. J. Obstet. Anaesth. 1:1992;159-166.
74. Douglas K.A., Redman C.W.G. Eclampsia in the United Kingdom. Br. Med. J. 309:1994;1395-1400.
75. Dubois D., Petitcolas J., Temperville B., Kleeper A., Catherine P.H. Treatment of hypertension in pregnancy with B-adrenoceptor antagonists. Br. J. Clin. Pharmacol. 13:1982;3755-3785.
76. Dudley D.K.L. Minibolus diazoxide in the management of severe hypertension in pregnancy. Am. J. Obstet. Gynecol. 151:1985;196-200.
77. Duley L. Maternal mortality associated with hypertensive disorders of pregnancy in Africa, Asia, Latin America and the Caribbean. Br. J. Obstet. Gynaecol. 99:1992;547-553.
78. Dunn R., Lee W., Cotton D.B. Evaluation of computerised axial tomography of eclamptic women with seizures refractory to magnesium sulphate therapy. Am. J. Obstet. Gynecol. 155:1986;267-268.
79. Eadie M.J. Metabolism of anticonvulsant drugs. Rev. Drug Metab. Drug Interact. 3:1981;317-347.
80. Eadie M.J. Anticonvulsant drugs: an update. Drugs. 27:1984;328-363.
81. Eadie M.J., Tyrer J.H. Neurological Clinical Pharmacology. 1980;Adis Press, Auckland.
82. Which convulsants for women with eclampsia. Evidence from the Collaborative eclampsia trial. Lancet. 345:1995;1455-1463.
83. ECPPA: randomized trial of low dose aspirin for the prevention of maternal and fetal complications in high risk pregnant women. Br. J. Obstet. Gynaecol. 103:1996;39-47.
84. Eisenbud F.G., Lobue C.C. Hypocalcemia after the therapeutic use of magnesium sulphate. Arch. Intern. Med. 136:1976;688-691.
85. Fabregues G., Alvarez L., Varas Juri P., Drisaldi S., Cerrato C., Moschettoni C., Pituelo D., Baglivo H.P., Esper R.J. Effectiveness of atenolol in the treatment of hypertension during pregnancy. Hypertension. 19:1992;129-131. (Suppl. 2).
86. Fairley K.F., Adey F.D., Ross I.C., Kincaid-Smith P. Heparin treatment in severe preeclampsia and glomerulo-nephritis in pregnancy. Lindheimer M.D., Katz A., Zuspan F.P. Hypertension in Pregnancy. 1976;103-112 John Wiley and Sons, New York.
87. Farmer J.B., Kennedy I., Levy G.P., Marshall R.J. Pharmacology of AH 5158: a drug which blocks both α and β-adrenoceptors. Br. J. Pharmacol. 45:1972;660-675.
88. Fidler J., Smith V., Fayres P., de Swiet M. Randomised controlled comparative study of methyldopa and oxprenolol in treatment of hypertension in pregnancy. Br. Med. J. 286:1983;1927-1930.
89. Finnerty F.A. Jr. Hypertension in pregnancy. Clin. Obstet. Gynecol. 18:1975;145-154.
90. Forrester T.E., Jones D., McCaw-Binns A., Palmer-Levy M., Wilks R., Bernard G.W., Fletcher H., Mullings A., Ashley D., Goldings J. Low-dose aspirin in pregnancy - are there any benefits? West Ind. Med. J. 45:1996;26-37. (Suppl. 2).
91. Foster T.S., Hamann S.R., Richards V.R., Bryant P.J., Graves D.A., McAlliste R.G. Jr. Nifedipine kinetics and bioavailability after single intravenous and oral doses in normal subjects. J. Clin. Pharmacol. 23:1983;161-170.
92. Franx A., Van der Post J.A.M., Van Montfrans G.A., Bruinse H.W., Gerard G.H.A. The fourth sound of korotkoff in pregnancy: a myth? Lancet. 347:1996;841.
93. Gagnon R.M., Morissette M., Presant S., Savard D., Lemire J. Haemodynamics and coronary effects of intravenous labetalol in coronary artery disease. Am. J. Cardiol. 49:1982;1267-1269.
94. Gallery E.D.M., Saunders D.M., Huynor S.N., Gyory A.Z. Randomised comparison of methyldopa and oxprenolol for treatment of hypertension in pregnancy. Br. Med. J. 1:1979;1591-1594.
95. Galley E.D., Rowe J., Campbell S., Hawkins T. The effect of serum on secretion of prostacyclin and endothelin-1 by decidual endothelial cells from normal and preeclamptic pregnancies. Am. J. Obstet. Gynecol. 173:1995;918-923. (3 Pt. 1).
96. Gant N.F., Madden J.D., Siiteri P.K., MacDonald P.C. The metabolic clearance rate of dehydroisonandrosterone sulphate. Am. J. Obstet. Gynecol. 123:1975;159-163.
97. Garden A., Davey D.A., Dommisse J. Intravenous labetalol and intravenous dihydralazine in severe hypertension in pregnancy. Clin. Exp. Hypertens. B1:1982;371-383.
98. Gedekoh R.H., Hayashi T.T., MacDonald H.M. Eclampsia at Magee - Women's Hospital, 1970 to 1980. Am. J. Obstet. Gynecol. 140:1981;860-866.
99. Gerber N., Wagner J.G. Explanation of the dose dependent decline of diphenylhydantoin plasma levels by fitting to the integrated form of Michaelis-Menten equation. Res. Commun. Chem. Pathol. Pharmacol. 3:1972;455-466.
100. Gill B.P., Bonnar J. Controlled study of subcutaneous heparin and dipyridamole in women at high risk of foetal growth retardation. Bonnar J., MacGillivary I., Symonds M. Pregnancy Hypertension. 1980;577-580 MTP, Lancaster.
101. Glazko A.J., Chnag T., Baukema J., Dill W.A., Goulet J.R., Buchanan R.A. Metabolic disposition of diphenylhydantoin in normal human subjects following intravenous administration. Clin Pharmacol. Ther. 10:1969;498-504.
102. Gleerup G., Winther K. Differential effects of non-specific beta-blockade and calcium antagonism on blood clotting mechanism. Am. J. Med. 86:1989;127-129. (Suppl. 4A).
103. Goodlin R.C. Fetal and maternal effects of sodium nitroprusside. Am. J. Obstet. Gynecol. 146:1983;350-351.
104. Griffiths J., Rotchell Y.E., Cruickshank J.K., Philips-Gay M., Stewart A., Farrell B., Ayers S., Duley L. The Barbados Low Dose Aspirin Study in Pregnancy (BLASP): a population based trial in a developing country with excess preeclampsia and perinatal mortality. West Ind. Med. J. 45:1996;26-27. (Suppl. 2).
105. Habib A., McCarthy J.S. Effects on the neonate of propanolol administered during pregnancy. J. Pediatr. 91:1977;808-811.
106. Hallak M., Berman R.F., Irtenkauf S.M., Evans M.I., Cotton D.B. Peripheral magnesium sulphate enters the brain and increases the threshold for hippocampal seizures in rats. Am. J. Obstet. Gynecol. 167:1992;1605-1610.
107. Hallak M., Berry S.M., Madincea F., Romero R., Evans M.I., Cotton D.B. Fetal serum and amniotic fluid magnesium concentrations with maternal treatment. Obstet. Gynecol. 81:1993;185-188.
108. Hanssens M., Keirse M.J.N.C., Vankelcom F., Van Assche F.A. Fetal and neonatal effects of treatment with angiotensin-converting enzyme inhibitors in pregnancy. Obstet. Gynecol. 78:1991;128-135.
109. Hauth J.C., Goldenberg R.L., Parker C.R. Jr., Philips J.B.I., Copper R.L., DuBard M.B., Cutter G.R. Low-dose aspirin therapy to prevent preeclampsia. Am. J. Obstet. Gynecol. 168:1993;1083-1091.
110. Hauth J.C., Goldenberg R.L., Parker C.R. Jr., Cutter G.R., Clives S.P. Low-dose aspirin: lack of association with an increase in abruptio placenta or perinatal mortality. Obstet. Gynecol. 85:1995;1055-1058.
111. Hauth J., Owen J., Thom E., Goldenberg R., Sibai B., McNellis D. Prevention of preeclampsia with low-dose aspirin in nullipara. J. Soc. Gynaecol. Invest. 3:1996;86A-89A.
112. Hein T.H.A. Cardiorespiratory arrest with laryngeal oedema in pregnancy-induced hypertension. Can. Anaesth. Soc. J. 31:1984;210-212.
113. Henderson-Smart D.J., Horvath J.S., Phippard A.F. Effect of antihypertensive drugs on neonatal blood pressure. Clin. Exp. Pharmacol. Physiol. 11:1984;351-354.
114. Heykants J., van Peer A., Woestenborghs R., Gould S., Mills J. Pharmacokinetics of ketanserin and its metabolite ketanserin-ol in man after intravenous, intramuscular and oral administration. Eur. J. Clin. Pharmacol. 31:1986;343-350.
115. Higuchi S., Sasaki H., Ido Y., Seki T. Pharmacokinetic studies on nicardipine hydrochloride, a new vasodilator, after repeated administration to rats, dogs, and humans. Xenobiotica. 10:1980;897-903.
116. Hirsawa K., Shen W.F., Kelly D.T., Roubin G., Tateda K., Shibrat J. Effect of food ingestion on nifedipine absorption and haemodynamic response. J. Clin. Pharmacol. 28:1985;105-107.
117. Hof R.P., Salzmann R., Siegel H. Selective effects of PN 200-110 (isradipine) on the peripheral circulation and the heart. Am. J. Cardiol. 59:1987;30B-36B.
118. Holt D.T., Bhamra R., Thorley K.J., Fowler M.B., Jackson G. High performance liquid chromographic measurement of atenolol: placental transfer and expression in breast milk. Br. J. Clin. Pharmacol. 14:1982;148-149.
119. Horvath J.S. Hypertension in pregnancy: "pre-eclamptic toxaemia" - a disease of the endothelium? Mod. Med. S. Afr. 18:1993;91-97.
120. Horvath J.S., Phippard A.F., Korda A.R., Henderson-Smart D.J., Child A., Tiller D.J. Clonidine-hydrochloride: a safe and effective antihypertensive agent in pregnancy. Obstet. Gynecol. 66:1985;634-638.
121. Houghton G.W., Richens A., Toseland P.A., Davidson S., Falconer M.A. Brain concentration of phenytoin phenobarbitone and primidone in epileptic patients. Eur. J. Clin. Pharmacol. 9:1975;73-78.
122. Hutler H.N., Licht J.H., Iinicki N.P., Singh S. Clinical efficacy and pharmacokinetics of clonidine in haemodialysis and renal insufficiency. J. Lab. Clin. Med. 94:1979;223-231.
123. Hutton J.D., James D.K., Stirrat G.M., Douglas K.A., Redman C.W. Management of severe pre-eclampsia UK consultants. Br. J. Obstet. Gynaecol. 99:1992;554-556.
124. Ingemarsson I., Wide-Swensson D., Andersson K.E., Arulkumaran S. Maternal and fetal cardiovascular changes after intravenous injection of isradipine to pregnant women. Drugs. 40:1990;58-59.
125. Israli Z.H., Dayton P.G. Metabolism of hydralazine. Drug Metab. Rev. 6:1977;283-305.
126. Low dose aspirin in the prevention and treatment of intrauterine growth retardation and pregnancy induced hypertension. Lancet. 341:1993;396-400.
127. Jannet D., Carbonne B., Sebban E., Milliez J. Nicardipine versus metoprolol in the treatment of hypertension during pregnancy. A randomised controlled trial. Obstet. Gynaecol. 84:1994;354-359.
128. Joekes A.M., Thompson F.D. Acute haemodynamic effects of labetalol and its subsequent use as an oral hypotensive agent. Br. J. Clin. Pharmacol. 3:1976;789S-793S.
129. Johenning A., Lindheimer M.D. Hypertension in pregnancy. Curr. Opin. Nephrol. Hypertens. 2:1993;307-313.
130. Johenning A.R., Karrison T.G., Barron W.M. Interobserver variability in the measurement of diastolic blood pressure in pregnancy. Hypertens. Pregn. 14:1995;301-311.
131. Johnson C.C. The actions and toxicity of sodium nitroprusside. Arch. Intern. Pharmacodyn. Ther. 35:1929;480-496.
132. Johnsson G., Regardh C.G. Clinical pharmacokinetics of beta-adrenoceptor blocking drugs. Clin. Pharmacokinet. 1:1976;233-263.
133. Jones H.M.R., Cummings A.J. A study of the transfer of alpha methyldopa to the human fetus and newborn infant. Br. J. Clin. Pharmacol. 6:1978;432-434.
134. Jones H.M.R., Cummings A.J., Setchell K.D.R., Lawson A.M. A study of the deposition of α-methyldopa in newborn infant following its administration to the mother for the treatment of hypertension during pregnancy. Br. J. Clin. Pharmacol. 8:1979;433-440.
135. Kincaid-Smith P. Hypertension in pregnancy. (review) Blood Press. 3:1994;18-23.
136. Kirshon B., Wasserstrum N., Cotton D.B. Should continuous hydralazine infusion be utilised in severe pregnancy-induced hypertension. Am. J. Perinatol. 8:1991;206-208.
137. Klarr J.M., Bhatt-Metha V., Donn S.M. Neonatal adrenergic blockade following single dose maternal labetalol administration. Am. J. Perinatol. 11:1994;91-93.
138. Kleinbloesem C.G., van Harten J., de Leede L.G.J., van Brummelen P., Breimer D.D. Nifedipine kinetics and dynamics during rectal infusion to steady state with an osmotic system. Clin. Pharmacol. Ther. 36:1984;396-401.
139. Kwan K.C., Foltz E.L., Breault G.O., Baer J.E., Totaro J.A. Pharmacokinetics of methyldopa in man. J. Pharmacol. Exp. Ther. 198:1976;264-277.
140. Lambert C.R., Hill J.A., Nichols W.W., Feldman R.L., Pepine C.J. Coronary and systemic hemodynamic effects of nicardipine. Am. J. Cardiol. 55:1985;652-656.
141. Lamont R.F., Dunlop P.D.M., Levene M.I., Elder M.G. Use of glucocorticoids in pregnancies complicated by severe hypertension and proteinuria. Br. J. Obstet. Gynaecol. 90:1983;199-202.
142. Lean T.H., Ratnam S.S., Sivasamboo R. Use of benzodiazepines in the management of eclampsia. J. Obstet. Gynaecol. Br. Commonw. 75:1968;856-862.
143. Lebrec D., Hadengue A., Gaudin C., Levron J.C., Fraitag B., Berhelot P., Benhamon J.P. Pharmacokinetics of ketanserin in patients with cirrhosis. Clin. Pharmacokinet. 12:1990;245-253.
144. Leitz F., Bariletto S., Gural R., Jaworsky L., Patrick J., Symchowicz S. Secretion of labetalol in breast milk of lactating women. Fed. Proc. 42:1983;500-511.
145. Leysen J.E., Awouters F., Kennis L., Laduron P.M. Receptor binding profile of R41468, a novel antagonist at 5-HT2 receptors. Life Sci. 28:1981;1015-1022.
146. Lieberman B.A., Stirrat G.M., Cohen S.L., Beard R.W., Pinker G.D., Belsey E. The possible adverse effects of propanolol on the fetus in pregnancies complicated by severe hypertension. Br. J. Obstet. Gynaecol. 85:1978;678-683.
147. Liedholm H., Melander A., Bitzen P.O. Accumulation of atenolol and metoprolol in human breast milk. Eur. J. Clin. Pharmacol. 20:1981;229-231.
148. Liedholm H., Waehlin-Bell E., Hanson A., Ingemarsson I., Melander H. Transplacental passage and breast milk concentrations of hydralazine. Eur. J. Clin. Pharmacol. 21:1982;417-423.
149. Lim K.H., Friedman S.A. Hypertension in pregnancy. Curr. Opin. Obstet. Gynecol. 5:1993;40-49.
150. Lin M.S., McNay J.L., Shepherd A.M., Keeton T.K. The response of plasma catecholamines to intravenous labetalol: a comparison with sodium nitroprusside. Clin Pharmacol. Ther. 34:1983;466-473.
151. Lo L.Y., Bye A. Specific and sensitive method for determination of aspirin and salicylic acid in plasma using reverse phase high performance liquid chromatography. J. Chromatogr. 181:1980;473-477.
152. Long P., Oats J. Pre-eclampsia in twin pregnancy - severity and pathogenesis. Aust. N. Z. J. Obstet. Gynaecol. 27:1987;1-5.
153. Louis S., Kutt H., Mcdowell F. Intravenous diphenyl-hydantoin in experimental seizures. 11. Effect on penicillin-induced seizures in the cat. Arch. Neurol. 18:1968;472-477.
154. Love S.J., Yek K., Kann J., Levitt M.J., Reitberg D.P. Effect of mode of administration on nifedipine pharmacokinetics. Clin. Pharmacol. Ther. 37:1985;209-215.
155. Lucas M.J., Leveno K.G., Cunningham F.G. A comparison of magnesium sulphate with phenytoin for prevention of pre-eclampsia. N. Engl. J. Med. 333:1995;201-205.
156. Lunell N.O., Garoff L., Grunewald C., Nisell H., Nylund L., Sarby B., Thornstrom S. Isradipine, a new calcium antagonist: effects on maternal and fetal hemodynamics. J. Cardiovasc. Pharmacol. 18:1991;S37-S40. (Suppl. 3).
157. Lunell N.O., Bondesson U., Grunewald C., Ingemarsson I., Nisell H., Wide-Swensson D.H. Transplacental passage of isradipine in the treatment of pregnancy induced hypertension. Am. J. Hypertens. 6:1993;110S-111S. (Suppl. 3).
158. Mabie W.C., Gonzales A.R., Sibai B.M., Amon E. A comparative trial of labetalol and hydralazine in acute management of severe hypertension complicating pregnancy. Obstet. Gynecol. 70:1987;328-331.
159. Maharaj B., Moodley J. Management of hypertension in pregnancy. Cont. Med. Educ. S. Afr. 12:1994;1581-1589.
160. Maharaj B., Moodley J., Khedun S.M., Madhanpall N., Van der Byl K. Intravenous isradipine in the management of severe hypertension in pregnancy: a pilot study. Blood Press. 3:1994;54-56. (Suppl. 3).
161. Maharaj B., Khedun S.M., Moodley J., Van der Byl K. Intravenous isradipine in the management of severe hypertension in pregnancy. Hypertens. Pregn. 16:1997;1-9.
162. Mancia G., Ferrari A., Gregorinin L. Methyldopa and neural control of circulation in essential hypertension. Am. J. Cardiol. 45:1980;1237-1243.
163. Martin J.N. Jr., Blake P.E., Perry K.G. Jr. The natural history of HELLP syndrome: patterns of disease progression and regression. Am. J. Obstet. Gynecol. 164:1991;1500-1513.
164. Martin L.E., Hopkins R., Bland R. Metabolism of labetalol by animals and man. Br. J. Clin. Pharmacol. 3:1976;695-710. (Suppl. 3).
165. Mason W.D., Winer N., Kochak G., Cohen I., Bell R. Kinetics and absolute bioavailability of atenolol. Clin. Pharmacol. Ther. 25:1979;408-415.
166. Mastrogiannis D.S., Kalter C.S., O'Brien W.F., Carlan S.J., Reece E.A. Effect of magnesium sulphate on plasma endothelin 1 levels in normal and preeclamptic pregnancies. Am. J. Obstet. Gynecol. 167:1992;1554-1559.
167. McAinsh J., Simpson W.T., Holmes B.F., Smith S., Hood D., Warren D. Atenolol kinetics in renal failure. Clin. Pharmacol. Ther. 28:1980a;302-309.
168. McAinsh J., Simpson W.T., Holmes B.F., Young Y., Ellis S.H. Bioavailability of atenolol formulations. Biopharm. Drug Dispos. 1:1980b;323-332.
169. McCubbin J.H., Sibai B.M., Abdella T.N., Anderson G.D. Cardiopulmonary arrest due to acute maternal hypermagnesemia. Lancet. i:1981;1058.
170. McNeil J.J., Anderson A.E., Louis W.J., Morgan D.J. Pharmacokinetics and pharmacodynamic studies of labetalol in hypertensive subjects. Br. J. Clin. Pharmacol. 8:1979;157S-161S.
171. Meuldermans W., Hendrickx J., Woestenborghs R., van Houdt J., Mostmans E., Knaeps F., Verluyten W., Heykants J. Absorption, metabolism and excretion of ketanserin in man after oral administration. Arzneimittelforschung. 3:1988a;789-794.
172. Meuldermans W., van Houdt J., Mostmans E., Knaeps F., Verluyten W., Heykants J. Plasma protein binding of ketanserin and its distribution in blood. Arzneimittelforschung. 38:1988b;794-800.
173. Meyer H., Wehinger E., Bosserk F., Scherling D. Nimodipine: synthesis and metabolic pathway. Arznemittelforschung. 33:1983;106-112.
174. Michael C.A. Use of labetalol in the treatment of severe hypertension during pregnancy. J. Clin. Pharmacol. 8:1979;211S-215S.
175. Mirkin B.L. Diphenylhydantoin: placental transport, fetal localization, neonatal metabolism and possible tetragenic effect. J. Pediatr. 78:1971;329-337.
176. Moodley J., Daya P. Eclampsia: a continuing problem in developing countries. Int. J. Gynaecol. Obstet. 44:1993;9-14.
177. Moodley J., Moodley V.V. Prophylactic anticonvulsant therapy in the hypertensive crisis of pregnancy: the need for a large randomized trial. Hypertens. Pregn. 13:1994;245-252.
178. Munsat T.L. Therapy of myotonia. A double-blind evaluation of diphenylhydantoin, procainamide and placebo. Neurology. 17:1967;359-367.
179. Myhre E., Rugstad H.E., Hansen T. Clinical pharmacokinetics of methyldopa. Clin. Pharmacokinet. 7:1982;221-233.
180. Naidu S., Moodley J., Botha J., McFadyen L. The efficacy of phenytoin in relation to serum levels in severe preeclampsia and eclampsia. Br. J. Obstet. Gynaecol. 99:1992;881-886.
181. Naidu S., Payne A.J., Moodley J., Hoffman M., Gouws E. Randomized trial assessing the effect of phenytoin and magnesium sulphate using transcranial Doppler ultrasound. Br. J. Obstet. Gynaecol. 103:1996;111-116.
182. Nakashima T., Inoki M., Nakanishi Y. Nifedipine serum concentrations: effect upon blood pressure and heart rate in normotensive volunteers. Eur. J. Drug Metab. Pharmacokinet. 9:1984;73-78.
183. Nakayama K., Kurihara J., Miyajima Y., Ishii K., Kato H. Calcium antagonist properties of nicardipine, a dihydropyridine derivative assessed in isolated cerebral arteries and cardiac muscle. Arznemittelforschung. 35:1985;687-693.
184. Report on high blood pressure in pregnancy. Am. J. Obstet. Gynecol. 163:1990;1689-1712.
185. Neil-Dwyer G., Bartlett J., McAinsh J., Cruickshank J.M. Beta adrenoceptor blockers and blood brain barrier. Br. J. Clin. Pharmacol. 11:1981;549-553.
186. Neilson J.P. Magnesium sulphate: the drug of choice in eclampsia. Br. Med. J. 311:1995;702-703.
187. Nelson K.B., Grether J.K. Can magnesium sulphate reduce the risk of cerebral palsy in very low birthweight infants? Paediatrics. 95:1995;263-269.
188. Nelson T.R. A clinical study of preeclampsia. J. Obstet. Gynecol. Br. Emp. 62:1955;48-57.
189. Neuman J., Weiss B., Rabello Y., Cabal I., Freeman R.K. Diazoxide for acute control of severe hypertension complicating pregnancy: a pilot study. Obstet. Gynecol. 53:1979;50-55.
190. Nightingale S.L. From the Food and Drug Administration: warning on the use of ACE inhibitors in second and third trimester of pregnancy. JAMA. 267:1992;2445.
191. Oates J.A., Gillespie L., Udenfriend S., Sjoersdsma A. Decarboxylase inhibition and blood pressure reduction by alpha methyl,4 dihydroxy-DL-phenylalanine. Science. 131:1960;1890-1891.
192. Odar-Cederlof I., Lunde P., Sjoqvist F. Abnormal pharmacokinetics of phenytoin in a patient with uraemia. Lancet. ii:1970;831-832.
193. Olsen S.F., Sorensen J.D., Secher N.J., Hedegaard M., Henrisken T.B., Hansen H.S., Grant A. Randomised controlled trial of effect of fish oil supplementation on pregnancy duration. Lancet. 339:1992;1003-1007.
194. Onwunde J.L., Lilford R.J., Hjartardottir H., Staines A., Tuffnell D. A randomised double blind placebo controlled trial of fish oil in high risk pregnancy. Br. J. Obstet. Gynaecol. 102:1995;95-100.
195. Otto J., Lesko J. Protein binding of nifedipine. J. Pharm. Pharmacol. 38:1986;399-400.
196. Ozumbia B.C., Ibe A.I. Eclampsia in Enugu, Eastern Nigeria. Acta Obstet. Gynecol. Scand. 72:1993;189-192.
197. Page I.A., Corcoran A.C., Dustan H.P., Koppanyi T. Cardiovascular actions of sodium nitroprusside in animals and hypertensive patients. Circulation. 11:1955;183-198.
198. Parker J.C., Gitelman H.J., McManus T.J. Role of Mg in the activation of Na-H exchange in dog red cells. Am. J. Physiol. 257:1989;C1038-C1041.
199. Parazzini F., Bortolus R., Chatenoud L., Restelli S., Bendetto C. Follow up of children in the Italian Study of Aspirin in Pregnancy. Lancet. 343:1994;1235.
200. Patel P., Bose D., Greenway C. Effect of prazosin and phenoxybenzamine and alpha and beta receptors mediated response in intestinal resistance and capacitance vessels. J. Cardiovasc. Pharmacol. 3:1981;1050-1059.
201. Pearson R.M. Pharmacokinetics and response to diazoxide in renal failure. Clin. Pharmacokinet. 2:1977;198-207.
202. Pennybacker J. Some observations on trigeminal neuralgia. Garland H. Scientific Aspects of Neurology. 1961;153-167 Churchill Llivingstone, Edinburgh.
203. Perry I.J., Beevers D.G. The definition of pre-eclampsia. Br. J. Obstet. Gynaecol. 101:1994;587-591.
204. Persson B., Pettersson A., Hedner T. Pharmacokinetics of ketanserin in patients with essential hypertension. Eur. J. Clin. Pharmacol. 32:1987;259-265.
205. Persson B., Heykants J., Hednet T. Clinical pharmacokinetics of ketanserin. Clin. Pharmacokinet. 12:1990;345-356.
206. Pettersson A., Gradin K., Hedner T., Persson B. Antihypertensive mechanism of action of ketanserin and some ketanserin analogues in SHR rats. Arch. Pharmacol. 329:1985;394-397.
207. Phippard A.F., Fischer W.E., Horvath J.S., Child A.G., Korda A.R., Henderson-Smart D., Duggin G.G., Tiller D.J. Early blood pressure control improves pregnancy outcome in primigravid women with mild hypertension. Med. J. Aust. 154:1991;378-382.
208. Pickles C.J., Symonds E.M., Broughton-Pipkin F. The fetal outcome in a randomised double blind controlled trial of labetalol versus placebo in pregnancy induced hypertension. Br. J. Obstet. Gynaecol. 96:1989;38-43.
209. Pickles C.J., Broughton-Pipkin F., Symonds E.M. A randomised placebo controlled trial of labetalol in the treatment of mild to moderate pregnancy induced hypertension. Br. J. Obstet. Gynaecol. 99:1992;964-968.
210. Pirhonen J.P., Erkkola R.U., Makinen J.I., Ekbald U.U. Single dose of labetalol in normotensive pregnancy: effect on maternal haemodynamics and uterine and fetal flow velocity waveforms. Biol. Neonate. 59:1991;204-208.
211. Price-Evans D.A., White T.A. Human acetylation polymorphism. J. Lab. Clin. Med. 63:1964;394-403.
212. Pritchard J.A. The use of magnesium ion in the management of eclamptogenic toxemias. Surg. Gynecol. & Obstet. 100:1955;131-140.
213. Pritchard J.A., Stone S.R. Clinical and laboratory observations on eclampsia. Am. J. Obstet. Gynecol. 99:1967;754-765.
214. Pritchard J.A., Cunningham F.G., Pritchard S.A. The Parkland Memorial Hospital protocol for treatment of eclampsia: evaluation of 245 cases. Am. J. Obstet. Gynecol. 148:1984;951-963.
215. Pruitt A.W., Dayton P.G., Patterson J.H. Disposition of diazoxide in children. Clin. Pharmacol. Ther. 14:1973;73-82.
216. Ramesch K.D., Sommers J. Pharmacokinetics and metabolism of nifedipine. Hypertension. 5:1983;II-18-II-24.
217. Ramesch K.D., Graefe K.H., Scherling D., Sommers J., Ziegler R. Pharmacokinetics and metabolism of calcium blocking agents nifedipine, nitrendipine and nimodipine. Am. J. Nephrol. 6:1986;73-89.
218. Redman C.W. Use of antihypertensive drugs in hypertension in pregnancy. Clin. Obstet. Gynecol. 4:1977;685-705.
219. Redman C.W. Eclampsia still kills (Review). Br. Med. J. Clin. Res. Ed. 29:1988;1209-1210.
220. Reece P.A., Cozamanig I., Zacest R. Selective high performance liquid chromatography assays for hydralazine and its metabolites in plasma of man. J Chromatogr. B Biomed. Appl. 181:1980;427-440.
221. Reid J.L., Elliot H.L. Methyldopa. Handbook on Hypertension. 5:1984;92-112. Ch. 4.
222. Reid J.L., Elliot H.L. Methyldopa. Doyle A.E. Clinical Pharmacology of Antihypertensive Drugs. 1984;Elsevier, Amsterdam.
223. Reubinoff B.E., Eldor A., Laufer N., Sadvosky E. Maternal haemorrhagic complications following prophylactic low-dose aspirin and dipyridamole therapy. Gynecol. Obstet. Invest. 33:1992;241-243.
224. Richards D.A., Maconochie J.G., Bland R.E., Hopkins R., Woodings E.P., Martin L.E. Relationship between plasma concentrations and pharmacological effects of labetalol. Eur. J. Clin. Pharmacol. 11:1977a;85-90.
225. Richards D.A., Prichard B.N.C., Boakes A.J., Tuckman J., Knight E.J. Pharmacological basis for antihypertensive effects of intravenous labetalol. Br. Heart J. 39:1977b;99-106.
226. Robert J.M., Redman C.W.G. Pre-eclampsia: more than pregnancy induced hypertension. Lancet. 341:1993;1447-1451.
227. Roberts J.M. Magnesium for preeclampsia and eclampsia. N. Engl. J. Med. 333:1995;250-251.
228. Robson R.H., Vishwanath M.C. Nifedipine and beta blockade as a cause of cardiac failure. Br. Med. J. 284:1982;104.
229. Rossouw H.J., Howarth G., Odendaal H.J. Ketanserin and hydralazine in hypertension in pregnancy - a randomised double-blind trial. S. Afr. Med. J. 85:1995;525-528.
230. Rowlatt R.J. Effect of maternal diazepam on the newborn. Br. Med. J. 1:1978;985-987.
231. Rubin P.C. Beta blockers in pregnancy. Br. J. Obstet. Gynaecol. 94:1987;292-294.
232. Rubin P.C., Scott P.J., Reid J.L. Prazosin disposition in young and elderly subjects. Br. J. Clin. Pharmacol. 12:1981;401-404.
233. Rubin P.C., Butters L., Clark D., Sumner D., Belfield A., Pledger D., Low R.A., Reid J.L. Obstetrics aspects of the use in pregnancy associated hypertension of the beta-adrenoceptor antagonist atenolol. Am. J. Obstet. Gynecol. 148:1984;389-392.
234. Rubin P.C., Butters L., Kennedy S. Atenolol in the management of essential hypertension during pregnancy. Br. Med. J. 301:1990;587-589.
235. Rudnicki M., Frolilich A., Fischer-Rasmussen W., McNair P. The effect of magnesium on maternal blood pressure in pregnancy-induced hypertension: a randomised double blind placebo controlled trial. Acta Obstet. Gynecol. 70:1991;445-450.
236. Rush W.R., Alexander O., Hall D.J., Cairncross L., Dow R.J., Graham D.J. Metabolism of nicardipine hydrochloride in healthy male volunteers. Xenobiotica. 16:1986;341-349.
237. Ryan G., Lange I.R., Naugler M.A. Clinical experience with phenytoin prophylaxis in severe pre-eclampsia. Am. J. Obstet. Gynecol. 161:1989;1297-1304.
238. Sachs J.R. Interaction of magnesium with sodium pump of human red cell. J. Physiol. 400:1988;575-591.
239. Sadeh M. Action of magnesium sulphate in the treatment of pre-eclampsia-eclampsia. Stroke. 20:1989;1273-1275.
240. Sanchez-Ramos L., Briones D.K., Kaunitz A.M., Delvalle G.O., Gaudier F.L., Walker C.D. Prevention of pregnancy-induced hypertension by calcium supplementation in angiotensin 11-sensitive patients. Obstet. Gynecol. 84:1994;349-353.
241. Sanchez-Ramos L., Adair C.D., Kaunitz A.M., Briones D.K., De Valle G.O., Delke I. Calcium supplementation in mild pre-eclampsia remote from term: a randomised double-blind clinical trial. Obstet. Gynecol. 85:1995;915-918.
242. Sandstrom B. Adrenergic beta-receptor blockers in hypertension of pregnancy. Clin. Exp. Hypertens. 1:1982;127-141.
243. Sankar D., Moodley J. Low dose diazoxide in the emergency management of severe hypertension in pregnancy. S. Afr. Med. J. 65:1984;279-280.
244. Saotome T., Minoura S., Terashi K., Sato T., Echizen H., Ishizaki T. Labetalol in hypertension during 3rd trimester of pregnancy: its antihypertensive effect and pharmacokinetic-dynamic analysis. J. Clin. Pharmacol. 33:1993;979-988.
245. Saunders N., Hammersley B. Magnesium for eclampsia. Lancet. 346:1995;788-789.
246. Scherjon S.A., Kok J.H., Oosting H., Zondervan H.A. Intra-observer and inter-observer reliability of the pulsatility index calculated from pulsed Doppler flow velocity waveforms in three fetal vessels. Br. J. Obstet. Gynaecol. 100:1993;134-138.
247. Schiff E., Mashiach S. The use of low-dose aspirin in pregnancy. Am. J. Reprod. Immunol. 28:1992;153-156.
248. Schmidt D., Kuferberg H.J. Diphenylhydantoin, phenobarbital and primidone in saliva, plasma and cerebrospinal fluid. Epilepsia. 16:1975;735-741.
249. Scott A., Owen O. Recent advances in the aetiology and management of pre-eclampsia. Br. J. Hosp. Med. 55:1996;476-478.
250. Scriabine A. Prazosin. Scriabine A. Pharmacology of Antihypertensive Drugs. 1980;151-160 Raven Press, New York.
251. Secher N.J., Olsen S.F. Fish-oil and preeclampsia. Br. J. Obstet. Gynaecol. 97:1990;1077-1079.
252. Secher N.J., Olsen S.F., Sorensen J.D. Fish-oil and preeclampsia. Br. J. Obstet. Gynaecol. 98:1991;738-740.
253. Sellers E.M., Koch-Weser J. Influence of intravenous injection rate on protein binding and vascular activity of diazoxide. Ann. NY Acad. Sci. 226:1973;319-332.
254. Shand D.G. Pharmacokinetic properties of the beta-adrenergic receptor blocking drugs. Drugs. 7:1974;39-47.
255. Shennan A., Gupta M., Halligan A., Taylor D.J., de Swiet M. Lack of reproducibility in pregnancy of Korotkoff phase IV as measured by mercury sphygmomanometry. Lancet. 347:1996;139-142.
256. Shoemaker C.T., Meyers M. Sodium nitroprusside for control of severe hypertensive disease of pregnancy: a case report and discussion of potential toxicity. Am. J. Obstet. Gynecol. 149:1984;171-173.
257. Shran F., Jaffe J.M., Gonasun L.M. Clinical pharmacokinetics of isradipine. Am. J. Med. 84:1988;80-89. (Suppl. 3B).
258. Sibai B.M. Treatment of hypertension in pregnant women. N. Engl. J. Med. 335:1996;257-265.
259. Sibai B.M., Anderson G.D. Hypertension in pregnancy. Gabbe S.G., Neibyl J.R., Simpson J.L. Obstetrics: Normal and Problem Pregnancies. 1991;993-1055 Churchill Livingstone, New York.
260. Sibai B.M., Ramanathan J. The case of magnesium sulphate in preeclampsia-eclampsia. Int. J. Obstet. Anaesth. 1:1992;167-175.
261. Sibai B.M., McCubbin J.H., Anderson J.D., Lipshitz J., Dilts P.V. Eclampsia. I. Observation from 67 recent cases. Obstet. Gynecol. 58:1981;609-613.
262. Sibai B.M., Gonzalez A.R., Mabie W.C., Moretti M. A comparison of labetalol plus hospitalization versus hospitalization alone in the management of pre-eclampsia remote for term. Obstet. Gynecol. 70:1987;323-327.
263. Sibai B.M., Barton J.R., Akl S., Sarinoglu C., Mercer B.M. A randomised prospective comparison of management of pre-eclampsia remote from term. Am. J. Obstet. Gynecol. 167:1992;879-884.
264. Sibai B.M., Caritis S.N., Thom E., Klebanoff M., McNellis D., Rocco L., Paul R.H., Romero R., Witter F., Rosen M., Depp R. Prevention of preeclampsia with low-dose aspirin in healthy nulliparous women. N. Engl. J. Med. 329:1993;1213-1218.
265. Sibai B.M., Gordon T., Thom E. Risk factors for preeclampsia in healthy nulliparous women: a prospective multicenter study. Am. J. Obstet. Gynecol. 172:1995;642-648.
266. Skajaa K., Forman A., Andersson K.E. Effects of magnesium on isolated human fetal and maternal uteroplacental vessels. Acta Physiol. Scand. 139:1990;551-559.
267. Skajaa K., Dorup I., Sandrostrom B. Magnesium intake and status and pregnancy outcome in a Danish population. Br. J. Obstet. Gynaecol. 98:1991;919-928.
268. Slater R.M., Wilcox F.L., Smith W.D. Phenytoin infusion in severe pre-eclampsia. Lancet. i:1987;1417-1421.
269. Smith H.M., Black J., Symchowicz S., Calesnick B. The relationship between diazoxide dose form and diazoxide blood levels, and the glucose tolerance in the human subjects. J. New Drugs. 5:1965;262-265.
270. Smith M.J., Aynsley-Green A., Redman C.W. Neonatal hypoglycaemia after prolonged maternal treatment with diazoxide. Br. Med. J. Clin. Res. 284:1982;1234-1239.
271. Spatling L., Spatling G. Magnesium supplementation in pregnancy - a double blind study. Hosp. Med. 10:1990;36-38.
272. Spero L. Epilepsy. Lancet. ii:1982;1319-1322.
273. Stanaszek W.F., Kellerman D., Brodgen R.N., Romankiewicz J.A. Prazosin-pharmacological properties and therapeutic use in hypertension and congestive heart failure. Drugs. 25:1983;339-384.
274. 2+ may act as a cofactor in ion channel function. Trends Neurosci. 11:1988;475-477.
275. Stenbaek O., Myhre E., Rugstad H.E., Arnold E., Hansen T. Pharmacokinetics of methyldopa in heathy man. Eur. J. Clin. Pharmacol. 12:1977;117-123.
276. Streissguth A.P., Treder R.P., Barr H.M., Shepherd T.H., Bleyer W.A., Sampson P.D. Aspirin and acetaminophen use by pregnant women and subsequent child IQ and attention decrements. Teratology. 35:1987;211-219.
277. Struthers A.D., Whitesmith R., Reid J.L. Metabolic and haemodynamic effects of increased circulating adrenaline in man. Effect of labetalol in alpha and blocker. Br. Heart J. 50:1983;277-281.
278. Taylor L.A., Twomey T.M., Schuch von Wintenau M. The metabolic fate of prazosin. Xenobiotica. 7:1977;357-364.
279. Thorpe J.M., Katz V.L., Campbell D., Cefalo R.C. Hypersensitivity to magnesium sulphate. Am. J. Obstet. Gynecol. 161:1989;889-890.
280. Timmis A.D., Fowler M.B., Jaggarao N.S.V., Chamberlain D.A. Labetalol infusion for the treatment of hypertension in acute myocardial infarction. Eur. Heart J. 1:1980;413-416.
281. Toward R., Kazda S. The cellular mechanism of action of nimodipine (BAY e9736), a new calcium antagonist. Br. J. Pharmacol. 67:1979;409-410.
282. Tranguilli A.L., Garzetti G.G., Tommaso G.D., Boemi M., Lucino E., Fumelli P., Romanini C. Nifedipine treatment in pre-eclampsia reverts the increased erythrocyte aggregation to normal. Am. J. Obstet. Gynecol. 167:1992;942-945.
283. Triedman H.M., Fishman R.A., Yahr M.D. Determination of plasma and cerebrospinal fluid levels of dilantin in the human. Trans. Am. Neurol. Assoc. 85:1960;166-170.
284. Tse L.S., Jaffe J.M. Pharmacokinetics of PN 200-110 (isradipine), a new calcium antagonist, after oral administration in man. Eur. J. Clin. Pharmacol. 32:1987;361-365.
285. Tuffnel D., O'Donovan P., Lilford R.J., Prys-Davies A., Thornton J.G. Phenytoin in pre-eclampsia. Lancet. ii:1989;273-274.
286. Twomey T.M., Hobbs D.C. Analysis of prazosin in plasma by a sensitive high performance liquid chromatographic fluorescence method. J. Pharm. Sci. 67:1978;1468-1469.
287. Tyrer J.H., Eadie M.J., Sutherland J.M., Hooper W.D. An outbreak of anticonvulsant intoxication in an Australian city. Br. Med. J. 4:1970;271-273.
288. Uji Y., Ikeda M., Geguchi T., Sugimoto T., Kobayashi S. Phase 1 study of KJK-945 (ketanserin-tartrate). J. Clin. Ther. Med. 4:1988;3-20. (Suppl. 1).
289. Ulmesten U., Andersson K.E., Wingerup T. Treatment of preterm labor with calcium antagonist nifedipine. Arch. Gynecol. 229:1980;1-5.
290. Van Nueten J.M., Jannsen P.A.J., Van Beek J., Xhonneaux R., Verbueren T.J., Vanhoutte P.M. Vascular effects of ketanserin (R41468), a novel antagonist at 5-HT2 receptors. J. Pharmacol. Exp. Ther. 218:1981;217-230.
291. Van Zwieten P.A., Timmermans P.B. Differential pharmacological properties of beta-adrenoreceptor blocking drugs. J. Cardiovasc. Pharmacol. 5:1983;S1-S7. (Suppl. 1).
292. Van Zwieten P.A., Timmermans P.B., Van Brummelen P. The role of α-adrenoceptors in hypertension and in antihypertensive drug treatment. Am. J. Med. 77:1984;17-25.
293. Velazquez H. Thiazide diuretics. Renal Physiol. 10:1987;184-197.
294. Verbesselt R., Mullie A., Tjandramaga T.B. The effect of food intake on the plasma kinetics and toleration of prazosin. Acta Ther. 2:1976;27-31.
295. Vernier I.R. Sodium nitroprusside: theory and practice. Postgrad. Med. J. 50:1974;576-581.
296. Vink G.J., Moodley J. The effect of low dose dihydralazine on the foetus in the emergency treatment of hypertension in pregnancy. S. Afr. Med. J. 62:1982;475-477.
297. Vink G.J., Moodley J., Philpott R.H. The effect of dihydralazine on the foetus in the treatment of maternal hypertension. Obstet. Gynecol. 55:1980;519-522.
298. Volker A., Kreye W. Sodium nitroprusside. Scribner A. Pharmacology of Antihypertensive Drugs. 1980;373-396 Raven Press, New York.
299. Voto L.S., Zin C., Neira J., Lapidus A.M., Margulies M. Ketanserin versus alpha-methyldopa in treatment of hypertension during hypertension: a preliminary report. J. Cardiovasc. Pharmacol. 10:1987;S101-S103.
300. Wacker J., Lewicka S., Haack D., Bastert G. Hypertension in pregnancy. J. Steroid Biochem. Mol. Biol. 45:1993;65-68.
301. Wacker J., Muller J., Grischke E.M., Unkels R., Bastert G. Antihypertensive therapy in pregnancy induced hypertension with urapidil. Zentralbl. Gynakol. 116:1994;271-273.
302. Wada Y., Satoh K., Taira N. Separation of the coronary vasodilator from the cardiac effects of PN 200-110, a new dihydropyridine calcium antagonist, in the dog heart. J. Cardiovasc. Pharmacol. 7:1985;190-196.
303. Waisman G.D., Mayorga L.M., Camera M.I., Vignola C.A., Martinotti A. Magnesium plus nifedipine: potentiation of hypotensive effect in pre-eclampsia. Am. J. Obstet. Gynecol. 159:1988;308-309.
304. Walker J.J., Greer I., Calder A.A. Treatment of acute pregnancy related hypertension: labetalol and hydralazine compared. Postgrad. Med. J. 59:1983;168-170.
305. Walss-Rodriguez R.J., Flores-Padilla L.M. Management of severe pre-eclampsia/eclampsia. Comparison between nifedipine and hydralazine as antihypertensive agents. Ginecol. Obstet. Mex. 61:1993;76-79.
306. Wan S.H., Koda R.T., Maronde R.F. Pharmacokinetics, pharmacology of atenolol and effect of renal disease. Br. J. Clin. Pharmacol. 7:1979;569-574.
307. Watt J.D., Philip E.E. Oral diuretics in pregnancy toxaemia. Br. Med. J. 1:1960;1807.
308. Weiner C.P., Socol M.L., Vaisrub N. Control of pre-eclamptic hypertension by ketanserin, a new serotonin receptor antagonist. Am. J. Obstet. Gynecol. 149:1984;496-500.
309. Welling P. Pharmacokinetics of thiazide diuretics. Biopharm. Drug Dispos. 7:1986;501-535.
310. Werler M.M., Mitchell A.A., Shapiro S. The relation of aspirin use during the first trimester of pregnancy to congenital cardiac defects. N. Engl. J. Med. 321:1989;1639-1642.
311. Wide-Swennson D.H., Ingemarsson I., Lunell N.O., Forman A., Skajaa K., Lindberg B., Marsal K., Andersson K.E. Calcium channel blockade (isradipine) in the treatment of hypertension in pregnancy: a randomised placebo-controlled study. Am. J. Obstet. Gynecol. 173:1995;872-878. (3 Pt. 1).
312. Wilensky A.T., Lowden J.A. Inadequate serum levels after intramuscular administration of diphenylhydantoin. Neurology. 31:1973;318-324.
313. Williams E.R., Morrissey J.R. A comparison of acebutolol with methyldopa in hypertensive pregnancy. Pharmacotherapeutica. 3:1983;487-491.
314. Williams K. Hypertension in pregnancy. Can. Fam. Physician. 41:1995;426-432.
315. Wood A.J., Phelan E.J., Simpson F.O. Cardiovascular effects of prazosin in normotensive and genetically hypertensive rats. Clin. Pharmacol. Physiol. 2:1975;297-305.
316. Woodbury D.A. Effect of diphenylhydantoin on electrolytes and radiosodium turnover in the brain and other tissues of normal, hyponatremic and postical rats. J. Pharmacol. Exp. Ther. 115:1955;74-95.
317. Geographic variation in the incidence of hypertension in pregnancy. Am. J. Obstet. Gynecol. 158:1988;80-83.
318. The hypertensive disorders of pregnancy. WHO Technical Report Series. 1987;World Health Organisation, Geneva. No 758.
319. Yilorkala O. Aspirin for the prevention of pre-eclampsia: where do we stand now? Acta Obstet. Gynecol. Scand. 74:1995;407-409.
320. Zeeman G.G., Dekker G.A., van Geijn H.P., Kraajenbrink A.A. Endothelial function in normal and pre-eclamptic pregnancy: a hypothesis. Eur. J. Reprod. Biol. 43:1992;113-122.
321. Zuspan F.P. Problems encountered in the treatment of pregnancy induced hypertension. A point of view. Am. J. Obstet. Gynecol. 131:1978;591-597.